TITLE

Ivax gains recommendation in Europe for injectable paclitaxel anticancer drug

PUB. DATE
March 2004
SOURCE
PharmaWatch: Cancer;March 2004, Vol. 3 Issue 3, p18
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
Reports on the European Medicines Evaluation Agency's recommendation of the extension of the marketing authorization for Ivax Corp.'s proprietary injectable Paclitaxel to include the treatment of metastatic breast cancer and metastatic ovarian cancer. Identification of Paclitaxel as the active pharmaceutical ingredient in Taxol, a drug marketed by Bristol-Myers Squibb for the treatment of cancers in both the U.S. and Europe.
ACCESSION #
13787876

 

Related Articles

  • Gemzar shows efficacy in breast cancer, says Eli Lilly.  // PharmaWatch: Cancer;Jul2007, Vol. 6 Issue 7, p9 

    The article reports on the promising outcomes of Gemzar, an anticancer drug designed by Eli Lily & Co. for the treatment of breast cancer. According to the author, the combination of Gemzar and Bristol-Myers Squibb's Taxol has shown positive results in breast cancer. Allen Melemed, medical...

  • NEOPLASMS.  // Monthly Prescribing Reference;Jan2010, Vol. 26 Issue 1, p230 

    The article offers information on several antineoplastic agents. Among the drugs given are Tarceva from Genentech Inc. for locally advanced or metastatic non-small cell lung cancer, Tykerb from GlaxoSmithKline for advanced or metastatic breast cancer, Megace from Bristol-Myers Squibb Co. for...

  • Bristol-Myers compound shows anti-cancer activity in phase II trials.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p7 

    Reports study findings showing that BMS-247550, an investigational tubulin polymerizing agent under development by Bristol-Myers, has demonstrated activity in metastatic breast cancer and non-small lung cancer. Components and mechanism of action of BMS-247500; Description of interim results from...

  • Aventis' breast cancer treatment proves more effective in comparison study.  // PharmaWatch: Cancer;November 2003, Vol. 2 Issue 11, p5 

    Reports on the findings of a clinical trial comparing the effectiveness of taxotere injection concentrate from Aventis SA and paclitaxel from Bristol-Myers Squibb Co. in treating metastatic breast cancer. Rate of overall response; Time to disease progression; Overall patient survival.

  • Change Comes to Paclitaxel After Ivax/BMS Patent. Jarvis, Lisa // Chemical Market Reporter;10/16/2000, Vol. 258 Issue 16, p5 

    Reports that the market for the active pharmaceutical ingredient (API) is ripe for change after Ivax's launching of its generic version of Bristol-Myer Squibb's (BMS) Taxol. North American companies that will produce paclitaxel API; Factor that will affect the future growth of API; Partnership...

  • This breast cancer drug is first in new class of chemo agents. Belden, Heidi // Drug Topics;12/10/2007, Vol. 151 Issue 23, p18 

    The article reports that the U.S. Food & Drug Administration has approved the anti-breast cancer agent ixabepilone from Bristol-Myers Squibb both as monotherapy and in combination with capecitabine. According to the author, the anticancer agent is indicated in patients with metastatic or locally...

  • Pharma: Other News To Note.  // BioWorld Today;11/5/2012, Vol. 23 Issue 215, p8 

    This article reports on the decision of the National Institute of Health and Clinical Excellence in Great Britain to recommend Bristol-Myers Squibb Co.'s Yervoy, which is approved in Europe for treating advanced metastatic melanoma, within the final appraisal determination.

  • Bristol plans two anti-cancer drugs.  // Hudson Valley Business Journal;10/22/2001-10/29/2001, Vol. 12 Issue 16, p26 

    Reports on Bristol-Myers Squibb Co.'s expansion of its Center for Biotechnology Development in Syracuse, New York to make two anti-cancer drugs. Background on the drugs; Significance of the move to the company.

  • Ipilimumab approved for melanoma in EU.  // Hem/Onc Today;8/25/2011, Vol. 12 Issue 16, p18 

    The article reports that the ipilimumab, marketed under the name Yervoy by Bristol-Myers Squibb, has been approved by the European Commission for the treatment of advanced melanoma in adults.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics